Researchers from University of Oklahoma Report New Studies and Findings in the Area of DNA Research (EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage)
By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators discuss new findings in DNA Research. According to news reporting originating in Oklahoma City, Oklahoma, by NewsRx journalists, research stated, "We have previously demonstrated the epidermal growth factor receptor (EGFR)-targeted hybrid plasmonic magnetic nanoparticles (225-NP) produce a therapeutic effect in human lung cancer cell lines in vitro. In the present study, we investigated the molecular mechanism of 225-NP-mediated antitumor activity both in vitro and in vivo using the EGFR-mutant HCC827 cell line."
The news reporters obtained a quote from the research from the University of Oklahoma, "The growth inhibitory effect of 225-NP on lung tumor cells was determined by cell viability and cell-cycle analysis. Protein expression related to autophagy, apoptosis, and DNA-damage were determined by Western blotting and immunofluorescence. An in vivo efficacy study was conducted using a human lung tumor xenograft mouse model. The 225-NP treatment markedly reduced tumor cell viability at 72 hours compared with the cell viability in control treatment groups. Cell-cycle analysis showed the percentage of cells in the G2/M phase was reduced when treated with 225-NP, with a concomitant increase in the number of cells in Sub-G1 phase, indicative of cell death. Western blotting showed LC3B and PARP cleavage, indicating 225-NP-treatment activated both autophagy-and apoptosis-mediated cell death. The 225-NP strongly induced gamma H2AX and phosphorylated histone H3, markers indicative of DNA damage and mitosis, respectively. Additionally, significant gamma H2AX foci formation was observed in 225-NP-treated cells compared with control treatment groups, suggesting 225-NP induced cell death by triggering DNA damage. The 225-NP-mediated DNA damage involved abrogation of the G2/M checkpoint by inhibiting BRCA1, Chk1, and phospho-Cdc2/CDK1 protein expression. In vivo therapy studies showed 225-NP treatment reduced EGFR phosphorylation, increased gamma H2AX foci, and induced tumor cell apoptosis, resulting in suppression of tumor growth. The 225-NP treatment induces DNA damage and abrogates G2/M phase of the cell cycle, leading to cellular apoptosis and suppression of lung tumor growth both in vitro and in vivo."
According to the news reporters, the research concluded: "Our findings provide a rationale for combining 225-NP with other DNA-damaging agents for achieving enhanced anticancer activity."
For more information on this research see: EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage. International Journal of Nanomedicine, 2014;9():3825-3839. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also DNA Research).
Our news correspondents report that additional information may be obtained by contacting S. Kuroda, University of Oklahoma, Hlth Sci Center, Stephenson Canc Center, Oklahoma City, OK 73104, United States. Additional authors for this research include J. Tam, J.A. Roth, K. Sokolov and R. Ramesh.
Keywords for this news article include: Oklahoma City, Oklahoma, United States, North and Central America, Apoptosis, DNA Damage, DNA Research, Deoxyribonucleic Acid, Emerging Technologies, Epidermal Growth Factor Receptor, Gastrointestinal Hormone Receptors, Gastrointestinal Hormones, Intercellular Signaling Peptides and Proteins, Membrane Proteins, Nanoparticle, Nanotechnology, Phosphotransferases, Protein Expression, Protein Kinases, Proteomics, Receptor Protein-Tyrosine Kinases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC